Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403

PURPOSE: The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR TKIs. We studied whether the combination of afatinib plus cetuximab compared with afatinib alone would improve progression-fr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Goldberg, Sarah B., Redman, Mary W., Lilenbaum, Rogerio, Politi, Katerina, Stinchcombe, Thomas E., Horn, Leora, Chen, Everett H., Mashru, Sandeep H., Gettinger, Scott N., Melnick, Mary Ann, Herbst, Roy S., Baumgart, Megan A., Miao, Jieling, Moon, James, Kelly, Karen, Gandara, David R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2020
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768342/
https://ncbi.nlm.nih.gov/pubmed/33021871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01149
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars